Bayer study 15791 - Mechanism of action (MoA) study 3month oral dosing of Vilaprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy

Hilary Critchley (Owner)
Catherine Murray (Creator)
Rohan Chodankar (Creator)
Alison Murray (Creator)
Moira Nicol (Creator)
Alistair Williams (Creator)

Dataset

Description

Essential source documentation for the study.

Date made available	2021
Publisher	Edinburgh DataVault
Geographical coverage	Lothian

Contact person

Hilary Critchley

DOI
10.7488/f58131b2-2532-47a6-8a50-a4a6aafd82d2

Mechanism of action (MoA) study 3month oral dosing of Vilprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy
Critchley, H. (Principal Investigator)
UK industry, commerce and public corporations
1/09/17 → 31/08/19
Project: Research
Mechanism of action (MoA) study 3month oral dosing of Vilprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy
Williams, A. (Principal Investigator)
UK industry, commerce and public corporations
1/09/17 → 31/08/19
Project: Research

Cite this

DataSetCite

Critchley, H. (Owner), Murray, C. (Creator), Chodankar, R. (Creator), Murray, A. (Creator), Nicol, M. (Creator), Williams, A. (Creator) (2021). Bayer study 15791 - Mechanism of action (MoA) study 3month oral dosing of Vilaprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy. Edinburgh DataVault. 10.7488/f58131b2-2532-47a6-8a50-a4a6aafd82d2

Bayer study 15791 - Mechanism of action (MoA) study 3month oral dosing of Vilaprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy

Description

Contact person

DOI

Projects

Mechanism of action (MoA) study 3month oral dosing of Vilprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy

Mechanism of action (MoA) study 3month oral dosing of Vilprisan or Ulipristal in patients with uterine fibroids scheduled for hysterectomy

Cite this